Abstract
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue Anil K. Rustgi, MD, has spent his career collaborating with a variety of researchers to address wide‐ranging problems in cancer treatment. In addition, adding talazoparib as a first‐line treatment for patients with newly diagnosed metastatic castrationresistant prostate cancer leads to a significant disease progression risk reduction compared to the standard of care, and the ENZAMET trial shows sustained improved overall survival for men with metastatic hormone‐sensitive prostate cancer treated with enzalutamide and testosterone suppression.